MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592453 | Name: Levodopa sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levodopa is the naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE.

Chemical Structure

Levodopa sodium
CAS#63302-01-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 592453

Name: Levodopa sodium

CAS#: 63302-01-2 (sodium)

Chemical Formula: C9H10NNaO4

Exact Mass: 197.0688

Molecular Weight: 219.17

Elemental Analysis: C, 49.32; H, 4.60; N, 6.39; Na, 10.49; O, 29.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
63302-01-2 (sodium) 59-92-7 (free base)
Synonym
Levodopa
IUPAC/Chemical Name
sodium (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
InChi Key
LRRQZAXMUDRSPC-RGMNGODLSA-M
InChi Code
InChI=1S/C9H11NO4.Na/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5;/h1-2,4,6,11-12H,3,10H2,(H,13,14);/q;+1/p-1/t6-;/m0./s1
SMILES Code
O=C([O-])[C@@H](N)CC1=CC=C(O)C(O)=C1.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine.
In vitro activity:
SH-SY5Y cells were treated with CA (carnosic acid) for 18 h, and then co-treated with 400 μM L-dopa for the indicated time points. The results showed that pretreatment of CA attenuated the cell death and nuclear condensation induced by L-dopa. In conclusion, CA ameliorates the development of LID via regulating the D1R signaling and prevents L-dopa-induced apoptotic cell death through modulating the ERK1/2-c-Jun and inducing the parkin. Reference: Front Pharmacol. 2021 Aug 9;12:703894. https://pubmed.ncbi.nlm.nih.gov/34434108/
In vivo activity:
These results confirm previous findings that rotenone-induced motor and non-motor problems were alleviated by the Active diet (AD). Levodopa showed an additive beneficial effect on rotarod performance in rotenone-treated mice fed with the AD. Reference: Front Aging Neurosci. 2018 Aug 3;10:237. https://pubmed.ncbi.nlm.nih.gov/30127735/

Preparing Stock Solutions

The following data is based on the product molecular weight 219.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Lai CY, Lin CY, Wu CR, Tsai CH, Tsai CW. Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells. Front Pharmacol. 2021 Aug 9;12:703894. doi: 10.3389/fphar.2021.703894. PMID: 34434108; PMCID: PMC8381221. 2. Li Z, Li X, He X, Jia X, Zhang X, Lu B, Zhao J, Lu J, Chen L, Dong Z, Liu K, Dong Z. Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma. Front Pharmacol. 2020 Sep 25;11:568459. doi: 10.3389/fphar.2020.568459. PMID: 33101026; PMCID: PMC7546765. 3. Perez-Pardo P, Broersen LM, Kliest T, van Wijk N, Attali A, Garssen J, Kraneveld AD. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. doi: 10.3389/fnagi.2018.00237. PMID: 30127735; PMCID: PMC6088190. 4. Park HJ, Joo HS, Kim YH, Kwon OK, Lee J, Kim ES, Moon DE. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. doi: 10.3349/ymj.2013.54.2.330. PMID: 23364964; PMCID: PMC3575974.
In vitro protocol:
1. Lai CY, Lin CY, Wu CR, Tsai CH, Tsai CW. Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells. Front Pharmacol. 2021 Aug 9;12:703894. doi: 10.3389/fphar.2021.703894. PMID: 34434108; PMCID: PMC8381221. 2. Li Z, Li X, He X, Jia X, Zhang X, Lu B, Zhao J, Lu J, Chen L, Dong Z, Liu K, Dong Z. Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma. Front Pharmacol. 2020 Sep 25;11:568459. doi: 10.3389/fphar.2020.568459. PMID: 33101026; PMCID: PMC7546765.
In vivo protocol:
1. Perez-Pardo P, Broersen LM, Kliest T, van Wijk N, Attali A, Garssen J, Kraneveld AD. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. doi: 10.3389/fnagi.2018.00237. PMID: 30127735; PMCID: PMC6088190. 2. Park HJ, Joo HS, Kim YH, Kwon OK, Lee J, Kim ES, Moon DE. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. doi: 10.3349/ymj.2013.54.2.330. PMID: 23364964; PMCID: PMC3575974.
1: Pelicioni PHS, Brodie MA, Latt MD, Menant JC, Menz HB, Fung VSC, Lord SR. Head and trunk stability during gait before and after levodopa intake in Parkinson's disease subtypes. Exp Gerontol. 2018 Jul 3;111:78-85. doi: 10.1016/j.exger.2018.06.031. [Epub ahead of print] PubMed PMID: 30017993. 2: Fahimi Z, Jahromy MH. Effects of blackberry (Morus nigra) fruit juice on levodopa-induced dyskinesia in a mice model of Parkinson's disease. J Exp Pharmacol. 2018 Jul 4;10:29-35. doi: 10.2147/JEP.S161782. eCollection 2018. PubMed PMID: 30013404; PubMed Central PMCID: PMC6037159. 3: Wu N, Wan Y, Song L, Qi C, Liu Z, Gan J. The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. Neuropsychiatr Dis Treat. 2018 Jul 5;14:1779-1786. doi: 10.2147/NDT.S162562. eCollection 2018. PubMed PMID: 30013350; PubMed Central PMCID: PMC6038854. 4: Mohamed D, Hegazy MA, Elshahed MS, Toubar SS, Helmy MI. Novel contribution to the simultaneous monitoring of pramipexole dihydrochloride monohydrate and levodopa as co-administered drugs in human plasma utilizing UPLC-MS/MS. Eur J Mass Spectrom (Chichester). 2018 Jan 1:1469066718788800. doi: 10.1177/1469066718788800. [Epub ahead of print] PubMed PMID: 30012017. 5: Antonini A, Nitu B. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm (Vienna). 2018 Jul 13. doi: 10.1007/s00702-018-1906-0. [Epub ahead of print] Review. PubMed PMID: 30006821. 6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501337/ PubMed PMID: 30000396. 7: Chung JW, Burciu RG, Ofori E, Coombes SA, Christou EA, Okun MS, Hess CW, Vaillancourt DE. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia. Neuroimage Clin. 2018 May 18;19:559-571. doi: 10.1016/j.nicl.2018.05.021. eCollection 2018. PubMed PMID: 29984164; PubMed Central PMCID: PMC6029579. 8: Picazio S, Ponzo V, Caltagirone C, Brusa L, Koch G. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. J Neurol. 2018 Jul 6. doi: 10.1007/s00415-018-8945-1. [Epub ahead of print] PubMed PMID: 29980853. 9: Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna). 2018 Jul 3. doi: 10.1007/s00702-018-1900-6. [Epub ahead of print] Review. PubMed PMID: 29971495. 10: Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol Dis. 2018 Jun 21;118:64-75. doi: 10.1016/j.nbd.2018.06.019. [Epub ahead of print] PubMed PMID: 29936234. 11: Ryan MB, Bair-Marshall C, Nelson AB. Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia. Cell Rep. 2018 Jun 19;23(12):3438-3446.e5. doi: 10.1016/j.celrep.2018.05.059. PubMed PMID: 29924988. 12: Fernandez-Pajarin G, Ares-Pensado B, Sesar A, Iglesias-Canle J, Masa-Vazquez L, Castro A. [Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease]. Rev Neurol. 2018 Jul 1;67(1):1-5. Spanish. PubMed PMID: 29923594. 13: Woitalla D, Dunac A, Safavi A, Ceravolo MG, Gomez Esteban JC, Pavese N, Asgharnejad M, Joeres L, Schuller JC, Chaudhuri KR. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. Expert Opin Pharmacother. 2018 Jun;19(9):937-945. doi: 10.1080/14656566.2018.1480721. Epub 2018 Jun 19. PubMed PMID: 29916262. 14: Cao C, Li D, Zeng K, Zhan S, Huang P, Li X, Sun B. Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study. Clin EEG Neurosci. 2018 Jun 1:1550059418781693. doi: 10.1177/1550059418781693. [Epub ahead of print] PubMed PMID: 29914268. 15: Müller T, Möhr JD. Long-term management of Parkinson's disease using levodopa combinations. Expert Opin Pharmacother. 2018 Jun;19(9):1003-1011. doi: 10.1080/14656566.2018.1484108. Epub 2018 Jun 18. PubMed PMID: 29913079. 16: Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, Espay AJ, Merola A. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. J Neurol. 2018 Jun 16. doi: 10.1007/s00415-018-8936-2. [Epub ahead of print] Review. PubMed PMID: 29909467. 17: Vo A, Seergobin KN, MacDonald PA. Independent effects of age and levodopa on reversal learning in healthy volunteers. Neurobiol Aging. 2018 May 18;69:129-139. doi: 10.1016/j.neurobiolaging.2018.05.014. [Epub ahead of print] PubMed PMID: 29894903. 18: García Esteban E, Cózar-Bernal MJ, Rabasco Álvarez AM, González-Rodríguez ML. A Comparative Study of Stabilizing Effect and Antioxidant Activity of Different Antioxidants on Levodopa-Loaded Liposomes. J Microencapsul. 2018 Jun 11:1-33. doi: 10.1080/02652048.2018.1487473. [Epub ahead of print] PubMed PMID: 29889613. 19: Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients. Eur J Clin Pharmacol. 2018 Jun 7. doi: 10.1007/s00228-018-2497-2. [Epub ahead of print] PubMed PMID: 29882153. 20: Pieterman M, Adams S, Jog M. Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease. Front Neurol. 2018 May 17;9:260. doi: 10.3389/fneur.2018.00260. eCollection 2018. PubMed PMID: 29867708; PubMed Central PMCID: PMC5966537.